Altrumed LLC

Device-agnostic Hypoxia Detection Software for Overdose Prediction and Positive Reversal Monitoring - Abstract / Project Summary Despite the Availability of Naloxone, Opioid Overdoses Claim 84,181 Lives Annually in the U.s., With an Additional Hidden Toll of Non-fatal Opioid Overdoses (NFOO) Leading to Hypoxia-induced Brain Injuries. Opioid-induced Respiratory Depression (OIRD) Remains the Primary Cause of Hypoxia-related Brain Injuries, Which Can Lead to Long-term Neurological Impairments Such as Encephalopathy, Cognitive Deficits, and Motor Dysfunction. These Injuries Begin Within Four Minutes of Hypoxia Onset, While Ems Response Times Average Over Nine Minutes. Furthermore, ~52% of Overdoses Occur When the Individual Is Alone, and Even in the Presence of Bystanders, 27% Fail to Recognize the Difference Between Opioid Use and a Potentially Fatal Overdose. to Address This, Dove Combines an Innovative Shoulder-wearable Sensor With Device-agnostic Software to Predict Fatal Overdoses and Facilitate Effective Reversal Interventions. Dove Integrates Advanced Algorithms That Analyze SPO2 Levels, Respiratory Rates, and Motion Patterns, Delivering Real-time Verbal Feedback Akin to an Automated External Defibrillator (aed). This Guidance Enables Responders—whether Harm Reduction Volunteers, Ems, or Law Enforcement—to Administer Tailored Interventions, Such as Naloxone Redosing or Bag-valve-mask (BVM) Ventilation. Importantly, Dove Addresses Challenges Posed by Novel Substances Like Xylazine, Which Impede Respiratory Recovery and Render Naloxone Insufficient. BVM, a Preferred Alternative Among 105 Harm Reduction Stakeholders Interviewed During Nih I-corps, Offers a More Humane and Effective Means of Restoring Oxygenation in Complex Overdose Scenarios. the Project Encompasses a One-year Phase I to Build on Our I-corps Participation to Validate Commercialization Potential. Phase I Focuses on Developing Device-agnostic Software for Hypoxia Monitoring and Validating Biomarkers for Overdose Prediction and Reversal. This Includes Stakeholder Feedback, Feasibility Analysis, and Fda Guidance, Laying the Groundwork for Phase Ii Clinical Trials.